

# Product News

## Anti-Redness Essentials

Revision Skincare introduces the Anti-Redness Essentials kit, an advanced solution for skin prone to redness and irritation that incorporates 5 products to calm, hydrate, and protect the skin while providing antiaging benefits. The kit includes the Gentle Cleansing Lotion, Soothing Facial Rinse, Hydrating Serum, Vitamin K Serum, and Intellishade Broad-Spectrum SPF 45 tinted moisturizer. For more information, visit [www.revisionskincare.com](http://www.revisionskincare.com).

## Hemangeol

Pierre Fabre Dermatologie obtains marketing authorization from the US Food and Drug Administration for the pediatric drug Hemangeol (propranolol hydrochloride), which is approved for proliferating infantile hemangioma requiring systemic therapy. Hemangeol is an oral solution developed for safe and effective use in children. It will be available in June 2014. This therapy fulfills an unmet medical need in the pediatric population that will benefit thousands of children. For more information, visit [www.pierre-fabre.com](http://www.pierre-fabre.com).

## Impavido

Paladin Labs Inc receives US Food and Drug Administration approval of Impavido (miltefosine) for the treatment of leishmaniasis. This oral therapy for the 3 main types of leishmaniasis—visceral, cutaneous, and mucosal—is intended for patients 12 years and older. It was granted fast-track designation, priority review, and orphan drug designation because of its potential to fill an unmet medical need for a serious disease. The product labeling includes a boxed warning that the drug can cause fetal harm and should not be given to pregnant women.

## Otezla

Celgene Corporation receives US Food and Drug Administration approval of Otezla (apremilast) to treat adults with active psoriatic arthritis. Otezla is an oral therapy that inhibits phosphodiesterase 4. For more information, visit [www.otezla.com](http://www.otezla.com).

## Professional-C Products

Obagi Medical Products, Inc, a division of Valeant Pharmaceuticals North America LLC, adds 2 products to the Professional-C line. Professional-C Suncare SPF 30 protects skin against damaging UVA and

UVB radiation and is formulated with vitamin C to complement collagen synthesis and brighten skin tone. Professional-C Peptide Complex offers a unique blend of ingredients that help minimize the visible signs of skin aging, promoting a healthy youthful glow. The product contains vitamin C, kinetin, zeatin, and acetyl octapeptide. For more information, visit [www.obagi.com](http://www.obagi.com).

## SOS Non-Ablative Post-Procedure Recovery Kit

Pierre Fabre Dermo-Cosmétique USA introduces the Avène SOS Non-Ablative Post-Procedure Recovery Kit, which joins the SOS Ablative Post-Procedure Recovery Kit and the SOS Complete Post-Procedure Recovery Kit for comprehensive care. The nonablative kit was created specifically for patients who have undergone nonablative laser, nonablative peel, or laser hair removal treatments. All 3 kits include easy-to-follow regimens to cool, soothe, and help restore fragile skin. Avène Thermal Spring Water cools the skin, relieving postprocedure irritation, inflammation, itching, and redness. A sterile facial compress prolongs the water-to-skin sensation and relief. Each kit contains a restorative product. In the nonablative kit, Cicalfate Post-Procedure Skin Recovery Emulsion helps heal the skin; the other 2 kits utilize Cicalfate Restorative Skin Cream. For more information, visit [www.aveneusa.com](http://www.aveneusa.com).

## Xolair

The US Food and Drug Administration grants approval for a new indication of Xolair (omalizumab) for the treatment of chronic idiopathic urticaria. This new use is for patients 12 years and older who remain asymptomatic despite treatment with H<sub>1</sub>-receptor antihistamine therapy. Xolair should not be used to treat other forms of urticaria and is not intended for children younger than 12 years. It is jointly developed by Genentech Inc and Novartis Pharma AG and is copromoted in the United States with Novartis Pharmaceuticals Corporation. This new treatment gives hope to patients who previously had no other options to consider. For more information, visit [www.gene.com](http://www.gene.com).

*If you would like your product included in Product News, please e-mail a press release to the Editorial Office at [cutis@frontlinemedcom.com](mailto:cutis@frontlinemedcom.com).*